BETHLEHEM, Pa., July 3, 2012 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it will hold a conference call covering the recent U.S. Food and Drug Administration approval of the OraQuick® In-Home HIV Test and the Company's plans to commercialize this product, at 8:00 am ET (5:00 am PT) on Thursday, July 5, 2012. To participate in the conference call, dial 877-348-9357 (Domestic) or 970-315-0488 (International) and reference Conference ID #98134091.
The conference call will also be webcast live and may be accessed on the Investor Relations page of OraSure's website, www.orasure.com. Please click on the webcast link and follow the prompts for registration and access 10 minutes prior to the call.
If you are unable to participate, a replay of the call will be archived on OraSure's website shortly after the call has ended and will be available for seven days. A replay of the call can also be accessed until midnight, July 12, 2012 by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering the Conference ID #98134091.
The OraSure Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6440
CONTACT: Judy ClarkeOraSure Technologies, Inc.
610-882-1820
investorinfo@orasure.com
Image: company logo
OraSure Technologies, Inc.
